Oncternal Therapeutics Inc (ONCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has a cash flow conversion efficiency ratio of -0.760x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.95 Million) by net assets ($9.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ONCT net asset quality score to measure how much of total assets are equity-financed.
Oncternal Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2002–2023)
This chart illustrates how Oncternal Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Oncternal Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Oncternal Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncternal Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trufin PLC
LSE:TRU
|
0.076x |
|
Heads UP Ventures Limited
NSE:HEADSUP
|
-0.078x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
Usha Martin Education & Solutions Limited
NSE:UMESLTD
|
0.019x |
|
Surya Oil & Gas Corp.
NASDAQ:SURY
|
0.011x |
|
Tijaria Polypipes Limited
NSE:TIJARIA
|
-0.154x |
|
Artelo Biosciences Inc
NASDAQ:ARTL
|
3.342x |
|
Goobit Group AB
ST:BTCX
|
0.705x |
Annual Cash Flow Conversion Efficiency for Oncternal Therapeutics Inc (2002–2023)
The table below shows the annual cash flow conversion efficiency of Oncternal Therapeutics Inc from 2002 to 2023. For the full company profile with market capitalisation and key ratios, see Oncternal Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $30.05 Million | $-32.16 Million | -1.070x | -77.78% |
| 2022-12-31 | $60.97 Million | $-36.70 Million | -0.602x | -99.52% |
| 2021-12-31 | $88.12 Million | $-26.59 Million | -0.302x | -94.81% |
| 2020-12-31 | $112.95 Million | $-17.50 Million | -0.155x | +86.76% |
| 2019-12-31 | $14.31 Million | $-16.75 Million | -1.170x | +22.35% |
| 2018-12-31 | $26.11 Million | $-39.35 Million | -1.507x | -145.76% |
| 2017-12-31 | $38.26 Million | $-23.46 Million | -0.613x | +41.30% |
| 2016-12-31 | $19.89 Million | $-20.78 Million | -1.045x | +90.31% |
| 2015-12-31 | $1.86 Million | $-20.04 Million | -10.777x | -568.13% |
| 2014-12-31 | $17.83 Million | $-28.76 Million | -1.613x | +60.81% |
| 2013-12-31 | $10.68 Million | $-43.97 Million | -4.116x | -429.03% |
| 2012-12-31 | $47.70 Million | $-37.11 Million | -0.778x | -68.98% |
| 2011-12-31 | $71.87 Million | $-33.09 Million | -0.460x | +21.99% |
| 2010-12-31 | $51.73 Million | $-30.53 Million | -0.590x | -111.23% |
| 2009-12-31 | $-8.75 Million | $-46.00 Million | 5.257x | +5854.26% |
| 2008-12-31 | $32.02 Million | $-2.92 Million | -0.091x | +80.84% |
| 2007-12-31 | $78.92 Million | $-37.63 Million | -0.477x | -303.85% |
| 2006-12-31 | $97.05 Million | $-11.46 Million | -0.118x | +75.05% |
| 2005-12-31 | $73.58 Million | $-34.82 Million | -0.473x | -92.99% |
| 2004-12-31 | $63.91 Million | $-15.67 Million | -0.245x | -383.43% |
| 2003-12-31 | $-150.23 Million | $-13.00 Million | 0.087x | -54.66% |
| 2002-12-31 | $-55.31 Million | $-10.55 Million | 0.191x | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more